Zeria/Tillotts in $100m-plus deal for CPP's FAP drug
This article was originally published in Scrip
Executive Summary
Tillotts Pharma and its parent Zeria have acquired development and commercialization rights in Europe and Japan to a therapy for familial adenomatous polyposis (FAP) being developed by Cancer Prevention Pharmaceuticals (CPP).